<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605419</url>
  </required_header>
  <id_info>
    <org_study_id>BEHGD-10-2020</org_study_id>
    <nct_id>NCT04605419</nct_id>
  </id_info>
  <brief_title>Calcium Electroporation in Patients With Cell Changes in the Esophagus</brief_title>
  <official_title>Calcium Electroporation in Patients With Barrett's Esophagus High-grade Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Patrick Achiam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this first-in-man study is to evaluate the safety of calcium electroporation used&#xD;
      in patients with Barrett's esophagus high-grade dysplasia through an endoscopic system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients give written informed&#xD;
      consent. Thereafter, patient will get calcium electroporation with biopsies and digital&#xD;
      photographs on day 0. We expect to discharge all patients same evening. Between day 3-7 an&#xD;
      examination is followed by gastroscopy with biopsies and digital photographs. On day 14 the&#xD;
      patients are followed in our outpatient clinic. 6 weeks after treatment the patients will&#xD;
      undergo endoscopic mucosa resection (EMR) or endoscopic submucosa dissection (ESD) surgery&#xD;
      and thereby the standard care of treatment for Barrett's esophagus high-grade dysplasia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with Barrett's esophagus high-grade dysplasia will get calcium electroporation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Registration of treatment related side effects assessed by CTCAE V 5.0</measure>
    <time_frame>Day 0 to 6 weeks after treatment</time_frame>
    <description>This is part of a safety evaluation and will be registered by CTCAE into Adverse Events (AE) and Serious Adverse Events (SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Registration of treatment related pain through a Visual Analogue Score (VAS)</measure>
    <time_frame>Day 0 to 6 weeks after treatment</time_frame>
    <description>Second part of safety evaluation which will be registered by VAS score. The VAS score is a scale with values from 0-10, where 0 is no pain and 10 is the worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of patient's that have gained from the treatment</measure>
    <time_frame>Day 0 to 6 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Barretts Esophagus With High Grade Dysplasia</condition>
  <arm_group>
    <arm_group_label>Calcium electroporation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Calcium electroporation</intervention_name>
    <description>Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation</description>
    <arm_group_label>Calcium electroporation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 years old.&#xD;
&#xD;
          2. Histological verified Barrett's esophagus high-grade dysplasia (BE HGD)&#xD;
&#xD;
          3. Expected survival &gt; 3 months.&#xD;
&#xD;
          4. Performance status Eastern Cooperative Oncology Group (ECOG)/World Health Organization&#xD;
             (WHO) ≤ 2.&#xD;
&#xD;
          5. Platelets ≥ 50 billion/l, International Normalized Ratio (INR) &lt; 1.5. Medical&#xD;
             correction is allowed, e.g. correction of a high International Normalized Ratio (INR)&#xD;
             using vitamin K.&#xD;
&#xD;
          6. Subjects must be willing and able to comply with the procedure, such as agreed&#xD;
             follow-up visits.&#xD;
&#xD;
          7. Sexually active men and fertile women must use adequate contraception during this&#xD;
             trial&#xD;
&#xD;
          8. Subjects must give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Coagulation disorder that cannot be corrected.&#xD;
&#xD;
          2. Subjects with a clinically significant cardiac arrhythmia.&#xD;
&#xD;
          3. Concurrent treatment with an investigational medicinal product&#xD;
&#xD;
          4. Patients with any other clinical condition or prior therapy that, in the opinion of&#xD;
             the investigator, would make the patient unsuitable for the study or unable to comply&#xD;
             with the study requirements.&#xD;
&#xD;
          5. Pregnancy or lactation&#xD;
&#xD;
        A medical doctor will always be responsible for final inclusion of the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Achiam, MD., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Department of Surgical Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Achiam, MD., Ph.D.</last_name>
    <phone>+45 35 45 04 41</phone>
    <email>Michael.Patrick.Achiam.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laser Bazancir, Med. student</last_name>
    <phone>+45 60 63 20 48</phone>
    <email>laser.arif.bazancir@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Region Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Achiam, Md., Ph.D.</last_name>
      <phone>+45 35 45 04 41</phone>
      <email>Michael.Patrick.Achiam.01@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Michael Patrick Achiam</investigator_full_name>
    <investigator_title>Consultant, MD, DMSci, Ph.D., FEBS-OG, Ass. Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

